Mr. Tao has over 25 years of experience practicing law in the PRC, focusing on debt m88 bonus equity financing by PRC companies in both domestic m88 bonus overseas markets, including advising issuers, underwriters m88 bonus investors in connection with IPO m88 bonus listing on Shanghai Stock Exchange (Main Board m88 bonus STAR Market), Shenzhen Stock Exchange (Main Board m88 bonus ChiNext), HKEX, NYSE m88 bonus NASDAQ, m88 bonus post-listing restructuring, mergers m88 bonus acquisitions, take-private m88 bonus re-listing transactions.

Mr. Tao’s most recent representative deals include: (a) acting as the issuer’s counsel to Amlogic (Shanghai) (2019), Suzhou Zelgen Biopharmaceuticals (2020) Chengdu-based HitGen (2020) m88 bonus Hinova Pharma (2022), in their initial public offering m88 bonus listing on the STAR Market of Shanghai Stock Exchange; (b) acting as the underwriters’ PRC counsel to BeiGene in its initial public offering m88 bonus listing on the STAR Market of Shanghai Stock Exchange in 2021; (b) acting as the underwriter’s PRC counsel to Microport Robotics (2021), New Horizon (2021), Vensyc (2020) in their initial public offering m88 bonus listing on HKEX, m88 bonus acting as the issuer’s PRC counsel to Vivo Biotech in its initial public offering m88 bonus listing on HKEX (2019); (c) acting as the underwriter’s PRC counsel to Dingdong in its initial public offering m88 bonus listing on NYSE in 2021; m88 bonus (d) representing NASDAQ m88 bonus Madrid-listed Grifols S.A. in its cross-border share swap with Shenzhen-listed SH RAAS in 2020, etc.

Mr. Tao has been selected as “Leading Lawyer” in capital market m88 bonus mergers m88 bonus acquisitions areas by Asialaw m88 bonus IFLR since 2012. He is also ranked as a “Recommended Lawyer” by Chambers in corporate m88 bonus commercial area (Bm88 bonus I) m88 bonus a “Stm88 bonus-out Lawyers” by Thomson Reuters in 2021.

B.A., Shm88 bonusong Normal University, 1991

LL.M. East China University of Politics m88 bonus Law, 2000